Golden State Wealth Management LLC Takes Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Golden State Wealth Management LLC acquired a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 754 shares of the biopharmaceutical company’s stock, valued at approximately $70,000.

Other large investors have also recently bought and sold shares of the company. nVerses Capital LLC acquired a new stake in shares of Gilead Sciences in the 3rd quarter worth approximately $25,000. HHM Wealth Advisors LLC grew its holdings in Gilead Sciences by 118.5% in the fourth quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 154 shares during the last quarter. Valued Wealth Advisors LLC increased its position in shares of Gilead Sciences by 101.9% in the third quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company’s stock valued at $27,000 after buying an additional 161 shares in the last quarter. YANKCOM Partnership acquired a new position in shares of Gilead Sciences during the 4th quarter worth $28,000. Finally, Decker Retirement Planning Inc. purchased a new stake in shares of Gilead Sciences in the 4th quarter worth about $29,000. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have issued reports on GILD shares. BMO Capital Markets lifted their target price on shares of Gilead Sciences from $94.00 to $102.00 and gave the stock an “outperform” rating in a research report on Thursday, November 7th. The Goldman Sachs Group upped their target price on Gilead Sciences from $74.00 to $84.00 and gave the company a “neutral” rating in a research note on Thursday, November 7th. Leerink Partners raised Gilead Sciences from a “market perform” rating to an “outperform” rating and raised their price target for the stock from $74.00 to $96.00 in a research report on Monday, October 21st. Daiwa America upgraded Gilead Sciences to a “hold” rating in a research report on Monday, November 18th. Finally, Wells Fargo & Company lifted their price objective on Gilead Sciences from $100.00 to $105.00 and gave the stock an “overweight” rating in a research report on Thursday, November 7th. Eleven equities research analysts have rated the stock with a hold rating, thirteen have given a buy rating and four have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $98.39.

Insider Activity

In other news, CFO Andrew D. Dickinson sold 248,645 shares of the business’s stock in a transaction dated Friday, November 29th. The shares were sold at an average price of $92.76, for a total value of $23,064,310.20. Following the completion of the sale, the chief financial officer now owns 138,919 shares of the company’s stock, valued at approximately $12,886,126.44. The trade was a 64.16 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Merdad Parsey sold 164,211 shares of the business’s stock in a transaction dated Wednesday, November 27th. The shares were sold at an average price of $91.92, for a total value of $15,094,275.12. Following the completion of the sale, the insider now directly owns 80,801 shares of the company’s stock, valued at approximately $7,427,227.92. This represents a 67.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 572,824 shares of company stock worth $53,611,715 over the last 90 days. Company insiders own 0.16% of the company’s stock.

Gilead Sciences Trading Down 0.6 %

NASDAQ:GILD opened at $95.48 on Tuesday. The business’s 50-day moving average is $93.04 and its two-hundred day moving average is $86.86. The firm has a market capitalization of $118.99 billion, a PE ratio of 1,060.89, a price-to-earnings-growth ratio of 1.25 and a beta of 0.18. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.26 and a quick ratio of 1.10. Gilead Sciences, Inc. has a 12 month low of $62.07 and a 12 month high of $100.51.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.